Drug intelligence / Profile preview

LASW1510

Development stage: Preclinical
Lead developer: Almirall

Overview

LASW1510 is an investigational drug evaluated in a double-blind, randomized, vehicle- and comparator-controlled, multi-center clinical trial for the treatment of actinic keratosis. It appears to be related to or compared with LAS41007 in clinical studies. Specific details about its mechanism of action, chemical structure, or pharmacological class are not available from current public sources[1][4].

Other names: LASW1510LASW-1510LASW 1510

Beyond the preview

Go deeper on LASW1510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LASW1510.

Explore the full profile